AC Immune SA
Developing precision medicine to diagnose, treat, and prevent neurodegenerative diseases.
ACIU | NDAQ
Overview
Corporate Details
- ISIN(s):
- CH0329023102
- LEI:
- Country:
- United States of America
- Address:
- EPFL INNOVATION PARK, BUILDING B, 0 1015 LAUSANNE
- Website:
- https://www.acimmune.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
AC Immune SA is a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases. The company focuses on developing innovative ways to diagnose, treat, and prevent conditions such as Alzheimer’s disease, Parkinson’s disease, and other rare neuro-orphan indications. Its broad and diversified pipeline is built on proprietary technology platforms and includes multiple treatment modalities, such as active immunotherapies, monoclonal antibodies, small molecule drugs, and diagnostic agents. These product candidates are designed to target and clear the pathological, misfolded proteins that are central to neurodegeneration. The company's scientific leadership and pipeline are validated through strategic collaborations with global pharmaceutical leaders.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all AC Immune SA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for AC Immune SA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for AC Immune SA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
